Category: BioMimetic Therapeutics Inc.
Wright Medical says it's not optimistic about an FDA dispute resolution panel this May on its Augment biologic bone graft.
Wright Medical (NSDQ:WMGI) said it's not optimistic about an FDA dispute resolution panel on its Augment biologic bone graft product, now slated for May, and would quickly move to cut costs at the BioMimetic Therapeutics subsidiary it bought back in 2012.
Wright Medical shares take a dive after it reveals a non-approvable letter from the FDA for the Augment bone graft it acquired along with BioMimetic Therapeutics last year.
Wright Medical (NSDQ:WMGI) shares are down nearly 9% today after the medical device company revealed that the FDA won't approve its Augment bone graft.
The medical device tax will have an inevitably negative effect on jobs in the medtech industry, BioMimetic Therapeutics founder Sam Lynch says.
MASSDEVICE ON CALL — The 1st payments for the 2.3% medical device tax which took effect this year are due at the end of the month, and the burden of those new fees will "absolutely, directly, negatively influence job growth," BioMimetic Therapeutics founder Sam Lynch told reporters.
Orthopedic medical device maker Wright Medical's company-wide overhaul is on or ahead of schedule in most areas, and the company is looking forward to closing the $390 million buyout of BioMimetic Therapeutics.
Orthopedic giant Wright Medical (NSDQ:WMGI) is back on track, CEO Robert Palmisano told an audience at the J.P. Morgan Healthcare conference in San Francisco yesterday.
Wright Medical Group picks up about 10 million shares of BioMimetic Therapeutics, for about a 36% stake, ahead of its planned merger next year.
Orthopedic devices maker Wright Medical signs a definitive agreement to acquire BioMimetic Therapeutics for cash and stock payments valued at $190 million with another $190 million in contingent payments, sending BMTI shares soaring on Wall Street.